Leerink Partnrs Issues Optimistic Forecast for EW Earnings

Key Points

• Analysts at Leerink Partners have raised their Q4 2025 EPS estimate for Edwards Lifesciences to $0.60, up from a previous estimate of $0.57, with a full-year earnings consensus of $2.45 per share.
• Several brokerages have given positive ratings on Edwards Lifesciences, with upgrades to "buy" and target prices ranging from $81.00 to $100.00, reflecting strong investor confidence.
• Despite a recent stock decline of 0.6%, Edwards Lifesciences maintains a market capitalization of $42.81 billion and is seen as having a moderate buy rating among analysts.

Edwards Lifesciences Corporation (NYSE:EW - Free Report) - Analysts at Leerink Partnrs boosted their Q4 2025 EPS estimates for Edwards Lifesciences in a report released on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now expects that the medical research company will post earnings of $0.60 per share for the quarter, up from their previous estimate of $0.57. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences' FY2026 earnings at $2.79 EPS, FY2028 earnings at $3.77 EPS and FY2029 earnings at $4.26 EPS.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company's revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the business posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS.

Several other brokerages also recently commented on EW. BTIG Research upgraded shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating and set a $100.00 target price on the stock in a report on Tuesday, July 29th. Stifel Nicolaus set a $85.00 price objective on shares of Edwards Lifesciences and gave the company a "buy" rating in a report on Monday, September 22nd. Piper Sandler upped their target price on shares of Edwards Lifesciences from $83.00 to $90.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Daiwa America raised shares of Edwards Lifesciences from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 29th. Finally, Canaccord Genuity Group raised their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a "hold" rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Edwards Lifesciences presently has an average rating of "Moderate Buy" and an average price target of $87.06.

Edwards Lifesciences Stock Down 0.6%

Edwards Lifesciences stock opened at $72.92 on Thursday. The company has a market capitalization of $42.81 billion, a P/E ratio of 10.49, a P/E/G ratio of 3.52 and a beta of 1.05. The firm's fifty day simple moving average is $77.72 and its 200-day simple moving average is $76.14. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06. Edwards Lifesciences has a 1-year low of $64.89 and a 1-year high of $83.00.

Institutional Investors Weigh In On Edwards Lifesciences

Several large investors have recently modified their holdings of the company. Quantbot Technologies LP bought a new position in shares of Edwards Lifesciences during the first quarter valued at about $26,000. SouthState Corp bought a new stake in Edwards Lifesciences during the 1st quarter worth approximately $27,000. Rosenberg Matthew Hamilton purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $28,000. Global X Japan Co. Ltd. grew its stake in Edwards Lifesciences by 116.1% in the 1st quarter. Global X Japan Co. Ltd. now owns 402 shares of the medical research company's stock worth $29,000 after buying an additional 216 shares in the last quarter. Finally, Tradewinds Capital Management LLC grew its stake in Edwards Lifesciences by 102.5% in the 1st quarter. Tradewinds Capital Management LLC now owns 405 shares of the medical research company's stock worth $29,000 after buying an additional 205 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the completion of the transaction, the insider directly owned 206,900 shares in the company, valued at approximately $16,150,614. The trade was a 4.15% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of the company's stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total transaction of $326,898.44. Following the transaction, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.